Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers

• DOI: 10.3390/microorganisms8111722
• Publication Date: 2020-11-04T01:46:52Z
• Authors: Frank Msafiri; Agricola Joachim; Kathrin Held; Yuka Nadai; Raquel Matavele C...; Christof Geldmacher; Said Aboud; Wolfgang Stöhr; Edna Viegas; Arne Kroidl; Muhammad Bakari; Patricia J. Munseri; Britta Wahren; Eric Sandström; Merlin L. Robb; Sheena McCormack; Sarah Joseph; Ilesh Jani; Guido Ferrari; Mangala Rao; Gunnel Biberfeld; Eligius Lyamuya; Charlotta Nilsson
• Keywords: HIV vaccine; V3 loop

Antibody responses that correlated with reduced risk of HIV acquisition in the RV144 efficacy trial were assessed healthy African volunteers who had been primed three times HIV-DNA (subtype A, B, C) and then randomized into two groups; group 1 was boosted twice HIV-MVA (CRF01_AE) 2 same coadministered subtype C envelope (Env) protein (CN54rgp140/GLA-AF). The fine specificity plasma Env-specific antibody mapped after final vaccination using linear peptide microarray technology. Binding IgG antibodies to V1V2 loop CRF01_AE Env IgA determined enzyme-linked immunosorbent assay. Functional antibody-dependent cellular cytotoxicity (ADCC)-mediating measured luciferase Mapping epitopes within HIV-1 demonstrated strong targeting V1V2, V3, immunodominant region gp41 both groups, additional recognition located C2 C4 regions 2. A high frequency V1V2-specific binding detected (77%) antigens (65%). In conclusion, coadministration CN54rgp140/GLA-AF did not increase frequency, breadth, or magnitude anti-V1V2 ADCC-mediating induced by boosting alone.